Find information on thousands of medical conditions and prescription drugs.

Eosinophilia-myalgia syndrome

Eosinophilia-myalgia syndrome is an incurable and sometimes fatal flu-like neurological condition that was caused by contaminated L-tryptophan supplements. Similar to regular eosinophilia, it causes an increase in eosinophil granulocytes in the patient's blood. more...

Home
Diseases
A
B
C
D
E
Ebola hemorrhagic fever
Ebstein's anomaly
Eclampsia
Ectodermal Dysplasia
Ectopic pregnancy
Ectrodactyly
Edwards syndrome
Ehlers-Danlos syndrome
Ehrlichiosis
Eisoptrophobia
Elective mutism
Electrophobia
Elephantiasis
Ellis-Van Creveld syndrome
Emetophobia
Emphysema
Encephalitis
Encephalitis lethargica
Encephalocele
Encephalomyelitis
Encephalomyelitis, Myalgic
Endocarditis
Endocarditis, infective
Endometriosis
Endomyocardial fibrosis
Enetophobia
Enterobiasis
Eosinophilia-myalgia...
Eosinophilic fasciitis
Eosophobia
Ependymoma
Epicondylitis
Epidermolysis bullosa
Epidermolytic hyperkeratosis
Epididymitis
Epilepsy
Epiphyseal stippling...
Epistaxiophobia
EPP (erythropoietic...
Epstein barr virus...
Equinophobia
Ergophobia
Erysipelas
Erythema multiforme
Erythermalgia
Erythroblastopenia
Erythromelalgia
Erythroplakia
Erythropoietic...
Esophageal atresia
Esophageal varices
Esotropia
Essential hypertension
Essential thrombocythemia
Essential thrombocytopenia
Essential thrombocytosis
Euphobia
Evan's syndrome
Ewing's Sarcoma
Exencephaly
Exophthalmos
Exostoses
Exploding head syndrome
Hereditary Multiple...
Hereditary Multiple...
Hereditary Multiple...
Hereditary Multiple...
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

In 1989 an outbreak of eosinophilia-myalgia syndrome was traced to an improperly prepared batch of tryptophan. The bacterial culture used to synthesise tryptophan had recently been genetically engineered to increase tryptophan production: unfortunately, with the higher tryptophan concentration in the culture medium, the purification process had also been modified to reduce costs, and a purification step that used charcoal absorption to remove impurities had been modified so that reduced amounts of charcoal were used. It is possible that one or more of these modifications allowed new or greater impurities through the purification. The specific impurity (or impurities) responsible for the toxic effects is still equivocal, although several impurities have been associated with the disease, and their chemical structures determined. Regardless of the origin of the toxicity, tryptophan was banned from sale in the US, and other countries followed suit. In February 2001, the FDA loosened the restrictions on the marketing of tryptophan (though not on importation).

Read more at Wikipedia.org


[List your site here Free!]


Eosinophilia-myalgia syndrome - Tips from Other Journals
From American Family Physician, 12/1/90

Eosinophilia and myalgia rarely coexist, except in cases of trichinosis, eosinophilic fasciitis, eosinophilic myositis, Churg-Strauss syndrome, hypereosinophilic syndrome and toxic oil syndrome. Recently, a syndrome of eosinophilia and severe myalgia has been associated with the consumption Of L-tryptophan. Martin and associates describe the clinical spectrum of eosinophilia-myalgia syndrome in 20 patients.

In all except one case, the patients met the Centers for Disease Control case definition of eosinophilia-myalgia syndrome (peripheral blood eosinophil count greater than 1,000 per mm[.sup.3] [1.0 X 10[.sup.9] per L), severe generalized myalgia and absence of other recognized causes).

Three of the patients developed eosinophilic fasciitis. Pneumonitis and myocarditis developed in one patient, neuropathy culminating in respiratory failure occurred in one, encephalopathy in one and fibrosis around the common bile duct in one patient. No association was apparent between the dosage of L-tryptophan or the duration of exposure and the syndrome. No organic contaminants could be identified in the preparations of L-tryptophan that were taken by the patients.

Biopsy specimens from 12 patients showed a mononuclear exudate with a variable number of eosinophils in affected tissues. Immunofluorescence showed major basic protein outside the eosinophils in affected tissues, indicating that toxic granule proteins were released in diseased organs.

L-Tryptophan was discontinued by all of the patients. Corticosteroids were prescribed for 16 of the patients. One patient received diuretics only. No drug therapy was prescribed for three patients. Four patients have recovered fully, while the others remain stable or are slowly recovering. One patient is gravely ill.

Although the pathologic alterations that occur in eosinophilia-myalgia syndrome are distinctive, the authors note that none are unique. Further study of this condition is warranted. (Annals of Internal Medicine, July 15, 1990, vol. 113, p. 124.)

COPYRIGHT 1990 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group

Return to Eosinophilia-myalgia syndrome
Home Contact Resources Exchange Links ebay